Arxxant’s Fate In Question After FDA Requests Additional Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly may seek a development partner for the diabetic retinopathy treatment to collect the three additional years of efficacy data sought by FDA.